PharmaShots | Incisive News in 3 Shots

Subscribe Now

Kesimpta

Top 20 Biopharma Companies of 2025

Top 20 Biopharma Companies of 2025

April 24, 2025

Top 20 Biopharma Companies of 2024

Top 20 Biopharma Companies of 2024

April 11, 2024

Novartis to Present Five-Year (ALITHIOS) Open-Label Extension Study Results of Kesimpta (ofatumumab) for Relapsing Multiple Sclerosis at AAN 2023

Novartis to Present Five-Year (ALITHIOS) Open-Label Extension Study Results of Kesimpta (ofatumumab) for Relapsing Multiple Sclero...

April 20, 2023

Novartis Presents Results of Kesimpta (ofatumumab) in P-III (ASCLEPIOS I/II) and (ALITHIOS) Open-Label Extension Trial for RMS at EAN 2022

Novartis Presents Results of Kesimpta (ofatumumab) in P-III (ASCLEPIOS I/II) and (ALITHIOS) Open-Label Extension Trial for RMS at...

June 28, 2022

Novartis Reports Results of Kesimpta (ofatumumab) in P-IIIb (ALITHIOS) OLE Study for the Treatment of Multiple Sclerosis

Novartis Reports Results of Kesimpta (ofatumumab) in P-IIIb (ALITHIOS) OLE Study for the Treatment of Multiple Sclerosis

March 3, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us